Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation

Kesavan, Suresh K.; Bhat, Shweta; Golegaonkar, Sandeep B.; Jagadeeshaprasad, Mashanipalya G.; Deshmukh, Arati; Patil, Harshal S.; Bhosale, Santosh D.; Shaikh, Mahemud L.; Thulasiram, Hirekodathakallu V.; Boppana, Ramanamurthy; Kulkarni, Mahesh J.

doi:10.1038/srep02941

Cited by 36 publications

(32 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar findings were observed within a streptozotocin mouse model of type 1 diabetes (T1DM) where hydralazine inhibited both formation and protein adduction of AGEs in plasma and kidney proteins. Within the same study, hydralazine decreased renal expression of receptor for AGE (rAGE) and NADPH oxidase (NOX), an interesting finding as these protein targets are upregulated via AGE activation and involved in AGE-rAGE mediated ROS production [27 • ]. Although translational studies investigating the aldehyde-scavenging abilities of hydralazine are limited, results from animal studies provide strong evidence that hydralazine is beneficial in sequestering biogenic aldehydes, thereby preventing downstream oxidative stress and vascular damage.…”

Section: Clinically Approved Agents With Aldehyde Scavenging Capacitiesmentioning

confidence: 99%

Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease

Nelson

Baba

Anderson

2017

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Aldehydes are continuously formed in biological systems through enzyme-dependent and spontaneous oxidation of lipids, glucose, and primary amines. These highly reactive, biogenic electrophiles can become toxic via covalent modification of proteins, lipids and DNA. Thus, agents that scavenge aldehydes through conjugation have therapeutic value for a number of major cardiovascular diseases. Several commonly-prescribed drugs (e.g., hydralazine) have been shown to have potent aldehyde-conjugating properties which may contribute to their beneficial effects. Herein, we briefly describe the major sources and toxicities of biogenic aldehydes in cardiovascular system, and provide an overview of drugs that are known to have aldehyde-conjugating effects. Some compounds of phytochemical origin, and histidyl-dipeptides with emerging therapeutic value in this area are also discussed.

show abstract

Section: Clinically Approved Agents With Aldehyde Scavenging Capacitiesmentioning

confidence: 99%

Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease

Nelson

Baba

Anderson

2017

Current Opinion in Pharmacology

View full text Add to dashboard Cite

show abstract

“…Also, in-vitro studies demonstrate that hydralazine, an antihypertensive agent, can reduce AGE formation by trapping reactive carbonyl compounds, leading to the modification of oxidative metabolism [72]. Hydralazine was also recently shown to reduce protein glycation with a reduction in RAGE, NADPH oxidase, and superoxide dismutase levels [73] in a murine model of diabetic nephropathy. In addition, inhibiting dipeptidyl peptidase-4, an enzyme that degrades incretins that promote insulin release and slow gastric emptying, has been shown to reduce AGE-mediated oxidative stress [74].…”

Section: Limiting the Endogenous Formation Of Advanced Glycation End mentioning

confidence: 99%

Advanced glycation end product accumulation

Mallipattu

Uribarri

2014

Current Opinion in Nephrology and Hypertension

View full text Add to dashboard Cite

Purpose of review The critical role of advanced glycation end products (AGEs) in the progression of chronic diseases and their complications has recently become more apparent. This review summarizes the recent contributions to the field of AGEs in chronic kidney disease (CKD). Recent findings Over the past 3 decades, AGEs have been implicated in the progression of CKD, and specifically diabetic nephropathy. Although numerous in-vitro and in-vivo studies highlight the detrimental role of AGEs accumulation in tissue injury, few prospective human studies or clinical trials show that inhibiting this process ameliorates disease. Nonetheless, recent studies have focused on the novel mechanisms that contribute to end-organ injury as a result of AGEs accumulation, as well as novel targets of therapy in kidney disease. Summary As the prevalence and the incidence of CKD rises in the United States, it is essential to identify therapeutic strategies that either delay the progression of CKD or improve mortality in this population. The focus of this review is on highlighting the recent studies that advance our current understanding of the mechanisms mediating AGEs-induced CKD progression, as well as novel treatment strategies that have the potential to abrogate this disease process. Video abstract http://links.lww.com/CONH/A12

show abstract

“…Interesting findings in Type 2 diabetes have emerged from proteomic studies carried out at NCL, Pune in human plasma and drug induced animal models [77–85]. One of the novel initiatives undertaken by this group is to study advanced glycation end products (AGE) in a diabetic animal model using MALDI–TOF–MS based proteomics [82]. …”

Section: Reviewmentioning

confidence: 99%

Proteomics in India: the clinical aspect

Mukherjee

Bandyopadhyay

2016

Clin Proteom

View full text Add to dashboard Cite

Proteomics has emerged as a highly promising bioanalytical technique in various aspects of applied biological research. In Indian academia, proteomics research has grown remarkably over the last decade. It is being extensively used for both basic as well as translation research in the areas of infectious and immune disorders, reproductive disorders, cardiovascular diseases, diabetes, eye disorders, human cancers and hematological disorders. Recently, some seminal works on clinical proteomics have been reported from several laboratories across India. This review aims to shed light on the increasing use of proteomics in India in a variety of biological conditions. It also highlights that India has the expertise and infrastructure needed for pursuing proteomics research in the country and to participate in global initiatives. Research in clinical proteomics is gradually picking up pace in India and its future seems very bright.

show abstract

Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation

Cited by 36 publications

References 47 publications

Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease

Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease

Advanced glycation end product accumulation

Proteomics in India: the clinical aspect

Contact Info

Product

Resources

About